Arialys is a private therapeutics company developing precision medicines for autoimmune neuropsychiatric disease. The field of autoimmune neuropsychiatry is rapidly evolving beyond well characterized encephalitis indications, with emerging evidence of elevated pathogenic autoantibodies in diseases including schizophrenia and dementia. Arialys’ lead therapeutic candidate (ART5803) is a monoclonal antibody designed to competitively inhibit auto-antibodies targeting the NMDA receptor and represents a potential first in class precision medicine for neuropsychiatric disease. ART5803 initial clinical assessment is planned for the second half of 2024 with proof-of-concept clinical studies in anti-NMDA receptor encephalitis (ANRE) initiating in 2025. Arialys is further assessing the therapeutic potential of ART5803 in broader psychosis indications.